StockData
Rapport Therapeutics, Inc. logo

Rapport Therapeutics, Inc. (RAPP) stock

RAPPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 7/30
$23.40−0.36 (-1.52%)

Close on Nov 18, 2026Market cap $1.12BP/E –Yield –

Rapport Therapeutics free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Rapport Therapeutics's free cash flow for the twelve months ending Sep 30, 2026 was -$121.18M. For fiscal 2025 it was -$88.09M.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$88.09M–
FY2024Dec 31, 2024-$67.23M–
FY2023Dec 31, 2023-$28.82M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$41.63M–
Q2 FY2026Jun 30, 2026-$41.53M–
Q1 FY2026Mar 31, 2026-$13.15M–
Q4 FY2025Dec 31, 2025-$24.87M–
Q3 FY2025Sep 30, 2025-$17.60M–
Q2 FY2025Jun 30, 2025-$25.09M–
Q1 FY2025Mar 31, 2025-$20.53M–
Q4 FY2024Dec 31, 2024-$14.67M–
Q3 FY2024Sep 30, 2024-$16.56M–
Q2 FY2024Jun 30, 2024-$17.32M–
Q1 FY2024Mar 31, 2024-$18.69M–
Q4 FY2023Dec 31, 2023-$11.79M–
Q3 FY2023Sep 30, 2023-$5.48M–

More Rapport Therapeutics figures

See a number that looks wrong?